28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
< 0.001). Receiver operating characteristic (ROC) analysis identified right hippocampal MD and t-tau as optimal classifiers for AD. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Out of 180 subjects, 74 showed short-term training gain transfer that was maintained over 3 months in 19 subjects. 5 key findings →
Participants: 235 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 225 patients (mean age 65.4 years, 54.2% male), MCR prevalence was 16.4%. 5 key findings →
Design: cross-sectional Participants: 225 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Animal studies indicate that Dang Gui Shao Yao San (DGSYS) may enhance cognitive function in VaD models through mechanisms such as antioxidation and the enhancement of cerebral blood flow. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Physical as well as cognitive training interventions improve specific cognitive functions but effects barely generalize on global cognition. 4 key findings →
Participants: 237 Evidence: low
Full summary, score breakdown and related studies → Original source
These results suggest pairing tDCS with cognitive training enhances functional connectivity and working memory performance in older adults, and thus may hold promise as a method for remediating age-related cognitive decline. 3 key findings →
Participants: 28 Evidence: low
Full summary, score breakdown and related studies → Original source
Along with rapid global population aging, the age-related cognitive disorders such as mild cognitive impairment (MCI) and dementia have posed a serious threat to public health, health care system, and sustainable economic and societal development of all countries. 1 key finding →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source
However, the brain plasticity associated with these proposed benefits of combined therapy has not yet been investigated in elderly subjects. 5 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source
A total of 73% of patients had a low coenzyme Q10 status. 5 key findings →
Participants: 73 Evidence: low
Full summary, score breakdown and related studies → Original source
When comparing SCD (N = 40) with NC (N = 45), mdALFFmean decreased at right inferior parietal lobule (IPL) of the frontoparietal network (FPN). 5 key findings →
Participants: 40 Evidence: low
Full summary, score breakdown and related studies → Original source
The levels of plasma ATN biomarkers (Aβ42/Aβ40 ratio, p-tua181, and NfL) were significantly changed in clinically diagnosed AD patients and they all associated with different domains of cognitive impairment. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our study revealed the possibility of urinary formic acid as a potential novel biomarker for the early diagnosis of AD. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
People with Down syndrome (DS) are at high risk for developing Alzheimer disease (AD). 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
For prediction of dementia in MCI, the AD signature cortical thickness biomarker performed better than hippocampal volume. 3 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our study reveals that PS in DLB is associated with specific deficits in attention and visuospatial/executive function, alongside more severe neuropsychiatric symptoms. 5 key findings →
Design: longitudinal study Participants: 35 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The Aβ-40 and tau levels were higher and the Aβ-42 level and Aβ-42/Aβ-40 ratio were lower in DS than in the controls (all p < 0.001). 5 key findings →
Participants: 62 Evidence: low
Full summary, score breakdown and related studies → Original source
The rate of cognitive decline among patients with amnestic mild cognitive impairment (aMCI) varies, and it is thus crucial to accurately predict the probability of cognitive deterioration in patients with MCI. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Language batteries used to assess the skills of elderly individuals, such as naming and semantic verbal fluency, present some limitations in differentiating healthy controls from patients with amnestic mild cognitive impairment (a-MCI). 1 key finding →
Participants: 77 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The global population is expected to have about 131.5 million people living with Alzheimer's disease (AD) and other dementias by 2050, posing a severe health crisis. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In 1907, Alois Alzheimer observed, as he quoted, development of "numerous fibers" and "adipose saccules" in the brain of his diseased patient Auguste Deter. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a late-onset dementia characterized by the deposition of amyloid plaques and formation of neurofibrillary tangles (NFTs) which lead to neuronal loss and cognitive deficits. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Genetic diversity in the apolipoprotein E (ApoE) gene has been identified as the major susceptibility genetic risk factor for sporadic Alzheimer’s disease (SAD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Participants with SSD exhibited a greater increase in plasma NfL levels and more pronounced declines in global cognition, memory, executive function, language, and processing speed over 2 years compared to non-SSD participants. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
CR was not associated with hippocampal GM MD and hippocampal GM volume. 5 key findings →
Participants: 38 Evidence: low
Full summary, score breakdown and related studies → Original source
Diabetes is a risk factor for Alzheimer disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →